The Global Short Bowel Syndrome Market is segmented on the Basis of Drug Class and Geography
Short Bowel Syndrome Market |
Short bowel syndrome (SBS) is a
malabsorption disorder brought on by inefficient small intestine function.
Diarrhea is one of the main signs of short bowel syndrome, and in the majority
of patients, it causes dehydration, malnutrition, and unexplained, significant
weight loss. SBS can cause complications like anaemia and kidney stones if it
is not treated.
With a 36% market share in 2019,
North America dominated the short bowel syndrome market. Due to an increase
in sedentary lifestyles that left less time for focusing on consuming wholesome
foods and an increase in the consumption of unhealthy and junk food, the market
for intestinal disorders that result from sedentary lifestyles has grown
rapidly in recent years. To support the R&D of SBS medications during the
forecast period of 2020–2025, public & private players in the US have
provided research grants. Additionally, it is anticipated that the unchecked
use of antibiotics and recent research initiatives and R&D expenditures in
the Asia-Pacific region will support the development of the SBS market.
According to the Crohn's &
Colitis Foundation of America, there were 10,000–20,000 cases of short bowel
syndrome reported in 2010; 25% of those cases result in complications within
two years of the initial diagnosis. As a result of the body's inability to
absorb nutrients at a sufficient rate, many children suffer from malnutrition
and pass away. According to Sancilio and Company, Inc., the majority of cases
of short bowel syndrome are brought on by congenital anomalies at birth, in
which the child dies before the age of six and the midgut rotates. The current
approach to treating infants with short bowel syndrome, according to Nutrinia
Ltd, includes appropriate nutritional, pharmaceutical, and surgical interventions.
Comments
Post a Comment